Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

CD34+ Positive Myelodysplastic Cells with Ring Sideroblasts or SF3B1 Mutation Produce High Erythroferrone and GDF15

Hiroto Horiguchi, MDPhD, Masayoshi Kobune, MD PhD, Kento Ono, MD, Saori Shimoyama, MD, Chisa Fujita, MD, Akari Goto, MDPhD, Hiroshi Ikeda, MDPhD, Satoshi Iyama, MD PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134861

Published: 2020

Journal Articles

Extravesicular Mir-7977 Released from Leukemic Cells Inhibites the PCBP1-Mediated mRNA Stabilization and Hippo-YAP Signaling Pathway in Bone Marrow Mesenchymal Stromal Cells

Masahiro Yoshida, MD PhD, Satoshi Iyama, MD PhD, Hiroto Horiguchi, MD PhD, Akari Goto, MD PhD, Shohei Kikuchi, MD PhD, Kazuyuki Murase, MD PhD, Kohichi Takada, MD PhD, Koji Miyanishi, MD PhD, Hiroshi Ikeda, MD PhD, Masahiro Maeda, MD PhD, Junji Kato, MD PhD, Masayoshi Kobune, MD PhD

Blood (2018) 132 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2018-99-111124

Published: 2018

Journal Articles

CD34/EPO-R Double Positive MDS Cells Produce Erythroferrone in Response to Erythropoietin

Blood (2016) 128 (22): 2455.

https://doi.org/10.1182/blood.V128.22.2455.2455

Published: 2016

Journal Articles

Next Generation Sequencing of CD138+ Myeloma Cells Could Predict Response Rate and Appropriate Therapy at Diagnosis

Hiroshi Ikeda, MD PhD, Yasushi Sasaki, MDPhD, Soushi Ibata, MD PhD, Masahiro Yoshida, MD, Ayumi Tatekoshi, Satoshi Iyama, MD PhD, Kazuyuki Murase, MD PhD, Kohichi Takada, MD PhD, Shohei Kikuchi, MD PhD, Tsutomu Sato, MD PhD, Masayoshi Kobune, MD PhD, Junji Kato, MD PhD

Blood (2016) 128 (22): 5609.

https://doi.org/10.1182/blood.V128.22.5609.5609

Published: 2016

Journal Articles

The Trifunctional Antibody (tri-31C2) Targeting CD38 and CD3 Has a Stronger Anti-Myeloma Effect Than the Chimeric Anti-CD38 Monoclonal Antibody (ch-31C2)

Tadao Ishida, MD PhD, Hiroshi Yasui, MD PhD, Kazuya Ishiguro, MD, Yuka Aoki, MD PhD, Hiroshi Ikeda, MD PhD

Blood (2016) 128 (22): 2097.

https://doi.org/10.1182/blood.V128.22.2097.2097

Published: 2016

Journal Articles

Extracellular Vesicle microRNAs from Acute Myeloid Leukemia Are Involved in the Regulation of Adherence Junction in Bone Marrow Microenvironment.

Blood (2016) 128 (22): 2863.

https://doi.org/10.1182/blood.V128.22.2863.2863

Published: 2016

Journal Articles

Addition of Bortezomib to Melphalan Plus Dexamethasone Provides Rapid Response in AL Amyloidosis

Toshiaki Hayashi, MD PhD, Tetsuyuki Igarashi, MD, Hiroshi Ikeda, MD PhD, Mitsufumi Nishio, MD PhD, Tadao Ishida, MD PhD, Yasuhisa Shinomura, MD PhD

Blood (2014) 124 (21): 5766.

https://doi.org/10.1182/blood.V124.21.5766.5766

Published: 2014

Journal Articles

B Type Natriuretic Peptide (BNP) Less Than 200 Pg/Ml Represents Good Candidate For High Dose Melphalan and Predicts Longer Survival In Systemic Light Chain Amyloidosis

Toshiaki Hayashi, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Yuka Aoki, M.D., Ph.D., Yumiko Maruyama, M.D., Ph.D., Tadao Ishida, M.D., Ph.D., Yasuhisa Shinomura, M.D., Ph.D.

Blood (2013) 122 (21): 5523.

https://doi.org/10.1182/blood.V122.21.5523.5523

Published: 2013

Journal Articles

Stroma cells and Monocytes make Multiple Myeloma Cells Active In Bone Marrow Microenviroment

Hiroshi Ikeda, MD, PhD, Tadao Ishida, M.D., Ph.D., Toshiaki Hayashi, M.D., Ph.D., Yuka Aoki, M.D., Ph.D., Yasuhisa Shinomura, M.D., Ph.D.

Blood (2013) 122 (21): 5333.

https://doi.org/10.1182/blood.V122.21.5333.5333

Published: 2013

Journal Articles

The Relationship of Myeloma Cells, Stromal Cells and Monocytes Under Bone Marrow Microenvironment

Hiroshi Ikeda, MD, PhD, Yuka Aoki, MD, Nasanori Nojima, MD, PhD, Hiroshi Yasui, MD, PhD, Toshiaki Hayashi, MD, PhD, Tadao Ishida, MD, PhD

Blood (2012) 120 (21): 4987.

https://doi.org/10.1182/blood.V120.21.4987.4987

Published: 2012

Journal Articles

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blood (2012) 119 (24): 5772–5781.

https://doi.org/10.1182/blood-2011-07-366633

Published: 2012

Includes: Supplemental data

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Blood (2010) 115 (25): 5202–5213.

https://doi.org/10.1182/blood-2009-12-259523

Published: 2010

Includes: Supplemental data

Journal Articles

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Teru Hideshima, Constantine Mitsiades, Hiroshi Ikeda, Dharminder Chauhan, Noopur Raje, Gullu Gorgun, Hiromasa Hideshima, Nikhil C. Munshi, Paul G. Richardson, Daniel R. Carrasco, Kenneth C. Anderson

Blood (2010) 115 (18): 3772–3775.

https://doi.org/10.1182/blood-2010-02-270082

Published: 2010

Includes: Supplemental data

Journal Articles

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.

Gullu Gorgun, PhD, Elisabetta Calabrese, MD, Teru Hideshima, MD, PhD, Giulia Perrone, MD, Giada Bianchi, MD, Hiroshi Ikeda, MD, PhD, Mala Mani, PhD, Yiguo Hu, MD, PhD, Diana Cristea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 950.

https://doi.org/10.1182/blood.V114.22.950.950

Published: 2009

Journal Articles

A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.

Gullu Gorgun, PhD, Elisabetta Calabrese, MD, Teru Hideshima, MD, PhD, Jeffrey Ecsedy, PhD, Giada Bianchi, MD, Mala Mani, PhD, Madhavi Bandi, Hiroshi Ikeda, MD, PhD, Giulia Perrone, MD, Yiguo Hu, MD, PhD, Yu-Tzu Tai, PhD, Mei Zheng, Diana Cristea, MD, Loredana Santo, MD, Daniel R. Carrasco, MD, PhD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3830.

https://doi.org/10.1182/blood.V114.22.3830.3830

Published: 2009

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

Loredana Santo, M.D., Teru Hideshima, MD., Ph.D., Erik A. Nelson, Ph.D, Diana Cirstea, MD, Madhavi Bandi, Ph.D, Hiroshi Ikeda, MD, PhD, Gullu Gorgun, PhD, Sonia Vallet, MD., Samantha Pozzi, MD, Giulia Perrone, MD, Kishan Patel, Yiguo Hu, Ph.D, Matthew S Squires, Murray Yule, Elisabetta Calabrese, MD., Dharminder Chauhan, Ph.D, Nikhil C. Munshi, Kenneth C. Anderson, MD, Noopur Raje, MD.

Blood (2009) 114 (22): 3833.

https://doi.org/10.1182/blood.V114.22.3833.3833

Published: 2009

Journal Articles

Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma.

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Hiroshi Ikeda, MD, PhD, Hannes Loferer, PhD, Giulia Perrone, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2009) 114 (22): 4915.

https://doi.org/10.1182/blood.V114.22.4915.4915

Published: 2009

NARROW

CD34+ Positive Myelodysplastic Cells with Ring Sideroblasts or SF3B1 Mutation Produce High Erythroferrone and GDF15

Extravesicular Mir-7977 Released from Leukemic Cells Inhibites the PCBP1-Mediated mRNA Stabilization and Hippo-YAP Signaling Pathway in Bone Marrow Mesenchymal Stromal Cells

CD34/EPO-R Double Positive MDS Cells Produce Erythroferrone in Response to Erythropoietin

Next Generation Sequencing of CD138+ Myeloma Cells Could Predict Response Rate and Appropriate Therapy at Diagnosis

The Trifunctional Antibody (tri-31C2) Targeting CD38 and CD3 Has a Stronger Anti-Myeloma Effect Than the Chimeric Anti-CD38 Monoclonal Antibody (ch-31C2)

Extracellular Vesicle microRNAs from Acute Myeloid Leukemia Are Involved in the Regulation of Adherence Junction in Bone Marrow Microenvironment.

Addition of Bortezomib to Melphalan Plus Dexamethasone Provides Rapid Response in AL Amyloidosis

B Type Natriuretic Peptide (BNP) Less Than 200 Pg/Ml Represents Good Candidate For High Dose Melphalan and Predicts Longer Survival In Systemic Light Chain Amyloidosis

Stroma cells and Monocytes make Multiple Myeloma Cells Active In Bone Marrow Microenviroment

The Relationship of Myeloma Cells, Stromal Cells and Monocytes Under Bone Marrow Microenvironment

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

PI3K/p110δ is a novel therapeutic target in multiple myeloma

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.

A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only